慢性HBV感染者免疫逃逸期与免疫控制期的临床特征分析

白萧萧; 东冰; 高红艳; 徐光华

doi:10.3969/j.issn.1001-5256.2018.12.012

慢性HBV感染者免疫逃逸期与免疫控制期的临床特征分析

DOI: 10.3969/j.issn.1001-5256.2018.12.012

延安大学附属医院感染科

基金项目:

科技惠民计划(2014HM-09)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1460
- HTML全文浏览量: 70
- PDF下载量: 363
- 被引次数: 0
出版历程
- 出版日期: 2018-12-20

Clinical features of immune escape phase and immune control phase of chronic HBV infection

Research funding:

摘要

摘要: 目的对慢性HBV感染者免疫控制期与免疫逃逸期的临床特征进行分析。方法选取2016年1月-2018年2月于延安大学附属医院门诊就诊或住院的"HBs Ag阳性、抗-HBe阳性、抗-HBc阳性"慢性HBV感染者226例,且均进行肝穿刺活组织检查。根据肝组织病理结果分为免疫控制期组[炎症活动度（A）<2且纤维化分期（F）<2者,121例]和免疫逃逸期组（A≥2或F≥2,105例）,比较分析两组患者的一般资料、病毒学、肝功能、肝硬度值（LSM）方面的差异。计量资料两组间比较采用独立样本t检验或Mann-Whitney U检验,计数资料两组间比较采用χ2检验。结果免疫控制期组与免疫逃逸期组在性别、年龄、乙型肝炎家庭聚集现象方面差异均无统计学意义（P值均>0.05）。两组患者的HBV DNA水平差异有统计学意义[1107. 00（369. 00～3876. 00） IU/ml vs 2171. 00（596. 00～8887. 00） IU/ml,Z=-2. 425,P=0. 015];但两组间HBs Ag和抗-HBc水平差异均无统计学意义（P值均> 0. 05）。免疫逃逸期...
- 肝炎病毒,乙型 /
- 肝炎表面抗原,乙型 /
- 肝炎抗体,乙型 /
- 活组织检查,针吸 /
- 对比研究
Abstract: Objective To investigate the clinical features of immune control phase and immune escape phase of chronic hepatitis B virus (HBV) infection. Methods A total of 226 patients with chronic HBV infection (with positive HBsAg, anti-HBe, and anti-HBc) who visited or were hospitalized in Yan'an University Affiliated Hospital from January 2016 to February 2018 were enrolled, and all of them underwent liver biopsy. According to the liver pathological results, the patients were divided into immune control group (121 patients with A <2 and F < 2) and immune escape group (105 patients with A≥2 or F≥2) . The two groups were compared in terms of general data, virology, liver function, and liver stiffness measurement (LSM) . The independent samples t-test or the Mann-Whitney U test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. Results There were no significant differences in sex, age, and family aggregation of hepatitis B between the immune control group and the immune escape group (all P > 0. 05) . There was a significant difference in HBV DNA level between the two groups [1107. 00 (369. 00-3876. 00) IU/ml vs 2171. 00 (596. 00-8887. 00) IU/ml, Z =-2. 425, P = 0. 015], while there were no significant differences in the levels of HBs Ag and anti-HBc (both P > 0. 05) . Compared with group A, group B had significantly higher levels of alanine aminotransferase (ALT) [46. 00 (22. 00-97. 50) U/L vs 30. 00 (19. 00-87. 50) U/L, Z =-2. 261, P = 0. 024], aspartate aminotransferase (AST) (35. 50 ±14. 74 U/L vs 31. 30 ± 12. 17 U/L, t =-2. 351, P = 0. 020) , and LSM (7. 41 ± 1. 51 k Pa vs 4. 76 ± 1. 23 k Pa, t =-9. 021, P <0. 001) . Conclusion Patients with chronic HBV infection (with positive HBsAg, anti-HBe, and anti-HBc) in the immune escape phase have significantly higher viral load, ALT, AST, and LSM than those in the immune control phase. In future, multicenter studies can be performed to clarify the ranges of the references values of the above parameters, in order to provide accurate diagnosis and treatment for patients with chronic HBV infection.
- hepatitis B virus /
- hepatitis B surface antigens /
- hepatitis B antibodies /
- biopsy, needle /
- comparative study

HTML全文

参考文献(12)

[1] LAMPERTICO P, AGARWAL K, BERG T, et al. EASL 2017clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67 (2) :370-398.

[2] LIU QC, LIN SW, HE HL, et al. Analysis on liver fibrosis features of HBeAg negative CHB patients with low viremia[J/CD]. Chin J Exp Clin Infect Dis:Electronic Edition, 2015, 9 (2) :186-190. (in Chinese) 刘启材, 林思炜, 何浩岚, 等.低病毒载量HBeAg阴性慢性乙型肝炎患者肝纤维化特征分析[J/CD].中华实验和临床感染病杂志:电子版, 2015, 9 (2) :186-190.

[3] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[4] TERRAULlT NA, BZOWEJ NH, CHANG KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63 (1) :261-283.

[5] SARIN SK, KUMAR M, LAU G, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015 update[J]. Hepatol Int, 2016, 10 (1) :1-98.

[6] World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[R]. Geneva:WHO, 2015.

[7] ZHANG P, DU HB, TONG GD, et al. Serum hepatitis B surface antigen correlates with fibrosis and necroinflammation:A multicentre perspective in China[J]. J Viral Hepat, 2018, 25 (9) :1017-1025.

[8] SHARIFI Z. Natural history of chronic hepatitis B virus infection based on laboratory testing[J]. Iran J Public Health, 2014, 43 (7) :990-993.

[9] ESMAEELZADEH A, SAADATNIA H, MEMAR B, et al. Evaluation of serum HBV viral load, transaminases and histological features in chronic HBe Ag-negative hepatitis B patients[J]. Gastroenterol Hepatol Bed Bench, 2017, 10 (1) :39-43.

[10] POKORSKA-S'PIEWAK M, KOWALIK-MIKOLAJEWSKA B, ANISZEWSKA M, et al. Predictors of liver disease severity in children with chronic hepatitis B[J]. Adv Clin Exp Med, 2016, 25 (4) :681-688.

[11] ZHANG XY, QIAN J, LI P, et al. Clinical value of noninvasive method in diagnosing hepatic fibrosis about chronic HBV carriers[J]. Chin J Hepatol, 2018, 26 (5) :332-336. (in Chinese) 张孝盈, 钱静, 李萍, 等.无创方法诊断慢性乙型肝炎病毒携带者肝纤维化的临床价值[J].中华肝脏病杂志, 2018, 26 (5) :332-336.

[12] HOU FQ, WANG GQ. Clinical value of anti-HBc quantification for chronic HBV infection[J]. J Clin Hepatol, 2018, 34 (5) :915-918. (in Chinese) 侯凤琴, 王贵强.慢性HBV感染者抗-HBc定量检测的临床意义[J].临床肝胆病杂志, 2018, 34 (5) :915-918.

施引文献

资源附件(0)

访问统计